BioMed Research International / 2015 / Article / Tab 1

Review Article

The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies

Table 1

Immune blocking antibodies treatments and status of clinical trials.

AntibodyTargetTrial IDCompanyCl. phasePatients numberTreatmentPrimary endpointStatusResults

TremelimumabCLTA-4NCT01008358
Interventional
Nonrandomized
Medimmune, USA, Pfizer, USAII21MonotherapyAntitumor and antiviral effectCompletedDisease control
rate of 76.4%
Median OS 8.2 month [95% CI: 4.64, 21.34]

TremelimumabCLTA-4NCT01853618
Interventional
Nonrandomized
Medimmune, USA, Pfizer, USAI RecruitingIn combination
with RFA or TACE
SafetyOngoingCompletion date: December 2015

IpilimumabCTLA-4N/ABristol-Myers Squibb, USAN/AN/AN/AN/AN/AN/A

NivolumabPD-1NCT01658878
Interventional
Nonrandomized
Bristol-Myers Squibb, USAIRecruiting
(target: 72)
MonotherapySafety/antitumor efficacy studyOngoingCompletion date:
May 2016

CT-011PD-1NCT00966251
Interventional
Nonrandomized
CureTech, IsraelI/II2MonotherapySafetyTerminatedStopped due to
slow accrual

LambrolizumabPD-1N/AMK-3475, Merck, USAN/AN/AN/AN/AN/AN/A

AMP-224PD-1N/AAmplimmune, USAN/AN/AN/AN/AN/AN/A

MEDI4376PD-L1MedImmune, USA, AstraZeneca, UKIRecruitingMonotherapySafety/antitumor efficacyOngoingN/A

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.